Bloomberg |
Lilly Diabetes Drug Jardiance Falls Short
Bloomberg Eli Lilly & Co.'s promising diabetes drug Jardiance fell short last quarter, a sign of the major challenges ahead for its new chief executive officer after recent setbacks on other potential new treatments. Jardiance's first-quarter sales, at $74 ... New diabetes meds push Lilly to earnings beat but pipeline worries abound SEC FORM 4 - SEC.gov |
Social Plugin